Banking

Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Cel-Sci (CVM) saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87. An over-80 RS Rating makes Cel-Sci stock a potential candidate for your watchlist.




X



When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price performance over the trailing 52 weeks matches up against other publicly traded companies.

History reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.


Looking For Winning Stocks? Try This Simple Routine


Is Cel-Sci Stock A Buy?

Cel-Sci stock has moved more than 5% past an 18.10 entry in a third-stage consolidation, meaning it’s now out of a proper buy range. Look for Cel-Sci stock to offer a new buying opportunity like a three-weeks-tight pattern or a pullback to the 50-day or 10-week line.

The maker of immunotherapy products reported a 12% earnings contraction in its most recent report. Revenue shrank by 100%.

Cel-Sci stock earns the No. 155 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN) and Maravai Lifesciences (MRVI) are also among the group’s highest-rated stocks.

YOU MIGHT ALSO LIKE:

Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button